Pilihan Pengobatan pada Pasien Psoriasis dengan HIV: Sebuah Tinjauan Sistematik
Article Sidebar
Main Article Content
Abstract
Psoriasis is a disease related to the immunity, usually inherited genetically and is chronic and recurring. When patients with psoriasis are infected with the Human Immunodeficiency Virus (HIV), the theory is that there is a paradoxical relationship that affects the two diseases. HIV can be a trigger for psoriasis and psoriasis can appear as an early symptom of HIV infection. The successful treatment of Psoriasis with HIV positive must be done appropriately according to the patient's condition. Here we discuss several Psoriasis therapy options in HIV positive patients based on several case reports that have a variety of different diseases. The research design is a literature review and refers to the PRISMA method. Scientific articles searchable on PubMed. There were 13 scientific articles related to Psoriasis patients who were HIV positive and met the inclusion criteria. Initial treatment of Psoriasis using biological therapy such as Risankizumab and Secukimab 300 mg subcutaneously, can change the response rate of the Psoriasis Area and Severity Index to 100 or the total loss of psoriasis lesions after a few weeks. In addition, the treatment of psoriasis together with High-active antiretroviral therapy (HAART) also affects the improvement of Psoriasis.
Article Details
References
Alpalhao M, C. J., & Filipe, P. (2019). Psoriasis In HIV Infection: An Update. InternationalInt J STD AIDS, 30(6), 596–604.
Arbune, Manuela., Arbune, Anca-Adriana., Niculet, Elena., Anghel, Lucretia., Fotea, Silvia., Tatu, A. L. (2022). Therapeutic Challenges Of Psoriasis In The HIV-Infected Patient: A Case Report. Exp Ther Med. https://doi.org/10.3892/etm.2021.11098
Bernardini, N., Skroza, N., Tolino, E., Marchesiello, A., Mambrin, A., B. V. (2022). HIV Positive Patient Treated With Ixekizumab. 25;173(3): https://doi.org/10.7417/CT.2022.2416.
Bowles, Alexandra A., Smirnov, B. (2019). ).Erythrodermic Psoriasis and HIV Infection. N Engl J Med, 380(1):80. https://doi.org/10.1056/NEJMicm1810005.
Bressler, Moshe Y., Pathak, Naeha., Rotblat, David., Tamez, R. (2021). Acute HIV Infection Presenting With Diffuse Plaque Psoriasis Treated With Highly Active Antiretroviral Therapy. Cureus, 13(11):e19. https://doi.org/10.7759/cureus.19680.
Catherine G, Mary., Sermswan, Peerada., Asawanonda, P. (2020). Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis. Case Rep Dermatol. 12;12(2):1. https://doi.org/10.1159/000508781
Cook, Olivia M., Knafo, Jenna., Bhaskar, Rahill., Salhab, Mohammad., Nguyen, H. (2022). Secondary Syphilis Presenting as Erythema Multiforme in the Setting of AIDS and Psoriasis. Cureus, 14(9):e291. https://doi.org/10.7759/cureus.29110
Edwards, Robert Jeffrey., Lavia, Leon Omari., Edwards, Jonathan., Boyce, G. (2022). Psoriasis in Patients Attending a Large HIV Clinic in Trinidad. Med Sci (Basel), 10(1). https://doi.org/10.3390/medsci10010009.
Fife, Douglas J., Waller, Jeanette M., Jeffes, Edward W., Koo, J. Y. M. (2007). Unraveling The Paradoxes Of HIV-Associated Psoriasis: A Review Of T-Cell Subsets And Cytokine Profiles.. Dermatol Online J.
Gong, Jian., Wu, Wewei., Qiu, Liguo., Wang, Xi., Bao, Jianwei., Wang, Jinjing., et al. (2022). Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report. Clin Cosmet Investig Dermatol. https://doi.org/10.2147/CCID.S395348
Gudjonsson, Johann E., Elder, J. T. (2019). Psoriasis. Fitzpatrick’s Dermatology, 1(9).
Kamiya, Koji., Kishimoto, Megumi., Sugai, Junichi., Komine, Mayumi., Ohtsuki, M. (2019). Risk Factors for the Development of Psoriasis. Int J Mol Sci, 20(18), 43–47. https://doi.org/10.3390/ijms20184347.
Kidron, Ariel., Nguyen, Hiep., N. H. (2022). Triumvirate Presentation and Treatment of Psoriasis in the Setting of HIV and Treponema pallidum Infection. Cureus, 11;14(2):e. https://doi.org/10.7759/cureus.22129.
Maliyar, Khalad., Lansang, Perla., Doiron, P. (2023). Use of risankizumab in two HIV-positive patients with psoriasis. 30(33), 54–55. https://doi.org/10.1016/j.jdcr.2023.01.015.
Mellyanawati, Palimbong, F., Kapantow, G. M., & Niode, N. J. (2019). Psoriasis Rupioid pada Pasien Pengidap Human Immunodeficiency Virus: Laporan Kasus. Jurnal Biomedik, 11(3), 162–165.
Sanguinetti, Juana., Suar, Lucila., Elimer, Lena., Busso, C. (2022). Successful treatment with risankizumab in a patient with psoriasis and HIV. Medicina (B Aires. 82(4), 605-608.
Shah, Bela J., Mistry, Deval., Chaudhary, N. (2019). Apremilast in People Living with HIV with Psoriasis Vulgaris: A Case Report. Indian J Dermatol, 64(3), 242–244. https://doi.org/10.4103/ijd.IJD_633_18.
Valenzuela, Fernando., Fernández, Javier., Margarita, Sánchez., Andrea, Z. (2018). Erythrodermic Psoriasis And Human Immunodeficiency Virus: Association And Therapeutic Challenges. An Bras Dermatol. 93(3):438-. https://doi.org/10.1590/abd1806-4841.20187387
Zarbafian, Misha., Cote, Benoit., Richer, V. (2019). Treatment Of Moderate To Severe Psoriasis With Apremilast Over 2 Years In The Context Of Long-Term Treated HIV Infection: A Case Report. SAGE Open Med Case Rep. 2019. https://doi.org/10.1177/2050313X19845193.